Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™.

Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

ASX: BOT | Share price


Change

Feb 4, 2021
April 6, 2017
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Herald Sun + Daily Telegraph | Sofpironium Bromide Story

🗞 MAKING HEADLINES Herald Sun Reporter, Owen Leonard,…

Euroz Hartleys Report | ‘Transformational Acquisition’

Botanix (ASX:BOT) is pleased to share a research report from…

Investor Webinar | May 2022

Botanix Pharmaceuticals (ASX: BOT) hosted an investor update…

Video Interview | Vince Ippolito

Botanix President and Executive Chairman, Vince Ippolito, is…

Small Caps Interview | Vince Ippolito

Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince…

New dermatology asset acquisition

Botanix has today announced acquisition of a novel dermatology…

Quarterly Activities Report and 4C Quarterly Cash Flow Report

Botanix (ASX:BOT) has today published its Quarterly Activities…

FDA grants new QIDP Designation Status for BTX 1801

Botanix is pleased to announce that the US Food and Drug Administration…

Check out our latest investor presentation

Sign up to receive our latest news

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere